Details of the Drug Combination

General Information of Drug Combination (ID: DCSASP4)

Drug Combination Name
SY-1425 PMID28870136-Compound-43
Indication
Disease Entry Status REF
Non-small cell lung carcinoma Investigative [1]
Component Drugs SY-1425   DMH8UF0 PMID28870136-Compound-43   DMWGV8N
N.A. Small molecular drug
High-throughput Screening Result Testing Cell Line: HOP-92
Zero Interaction Potency (ZIP) Score: 8.05
Bliss Independence Score: 12.33
Loewe Additivity Score: 1.27
LHighest Single Agent (HSA) Score: 1.27

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of SY-1425
Disease Entry ICD 11 Status REF
Acute myeloid leukaemia 2A60 Phase 1 [2]
Myelodysplastic syndrome 2A37 Phase 1 [2]
SY-1425 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Retinoic acid receptor alpha (RARA) TTW38KT RARA_HUMAN Agonist [2]
------------------------------------------------------------------------------------
PMID28870136-Compound-43 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Ecto-5'-nucleotidase (CD73) TTK0O6Y 5NTD_HUMAN Inhibitor [3]
------------------------------------------------------------------------------------

References

1 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Ectonucleotidase inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2017 Dec;27(12):1291-1304.